Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ImmunoGen -- Ignore unavailable to you. Want to Upgrade?

To: tom pope who wrote (5527)	2/28/2013 9:58:30 PM
From: Gary Mohilner	Respond to of 5665

It's my belief that IMGN will gradually become an earnings play as sales in T-DM1 grow dramatically with every quarter for the foreseeable future. This quarter will only have 3 weeks of sales, hardly enough to even report, but next quarter I believe we'll see sales reach over $100 million if Roche is pushing this as hard as I believe they are. I cannot remember a product being approved where it was announced it would be available to sell in 2 weeks, many companies take months to a year to put together distribution and sales. I wouldn't be at all surprised if sales this year went over $1 billion, and they should go up by that much or more in succeeding years. Even at under 5% royalties, investors will be impressed with IMGN's earnings. Gary